medigraphic.com
ISSN 1995-9427 (Print)

2019, Number 2

<< Back Next >>

Invest Medicoquir 2019; 11 (2)

Heberprot-p in the treatment of the ischemic diabetic foot with high risk of amputation

Alfonso SA, Rodríguez Valdés-Fauly C, Verde AL

Language: Spanish
References: 15
Page:
PDF size: 371.32 Kb.


ABSTRACT

Diabetes Mellitus is postulated as one of the great epidemics of the 21st century, with diabetic foot being one of its biggest complications due to the high number of hospital services. The association with a chronic peripheral arterial disease the possibility of a major amputation increases with the consequent loss of the quality of life and decreasing the life expectancy. We present the result of treatment with Recombinant Human Epidermal Growth Factor (Heberprot-p) in a patient with a high risk of major amputation, due to ischemic diabetic foot, associated with critical ischemia of the lower extremity after revascularization surgery due to aortoiliac occlusion. In a satisfactory manner, intralesional treatment of Heberprot-p was possible, applying 24 doses, with which more than 90% of granulation was achieved with consequent scarring, avoiding the amputation of the limb and improving the quality of life.


REFERENCES

  1. Kasper DL. Longo DL, Fauci AS, Hauser SL, Jameson JL, et al. Powers AC Diabetes Mellitus: Diagnostic, Classification and Patophysiology. Harrison's principles of internal medicine. 2018 :Vol 2 (19a edn.), New York: McGraw-Hill, pp: 2399-2407.

  2. World Health Organization Global Reports on Diabetes. 2016.

  3. Jara Albarrán A. Diabetes Mellitus. Clasificación. Epidemiología. In: Sanchez García-Cervigón P, Jara Albarrán A, editors. Endocrinología. 2nd ed. Argentina, Panamericana; 2010. p. 617.

  4. Organización Mundial de la Salud (OMS) [Internet]. OMS; 2015 [updated Enero 2015; cited 14/10/2015]. Disponible en: http://www.who.int/mediacentre/factsheets/fs312/es/.

  5. MINSAP. Anuario estadístico de salud 2015. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud [Internet]. 2015 [citado 2017 Nov 24]. Disponible en: http://files.sld.cu/dne/files/2016/04/Anuario_2015_electronico-1.pdf

  6. MINSAP. Anuario estadístico de salud 2018. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud [Internet]. 2018 [citado 2019 may 27]. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/

  7. Campos Acosta Y, Melgarejo Rivero B, Jaime Cabrera Z, Pol Marrón N, Vargas Machirán E, Pérez Leonard D, et al. Comportamiento de la función renal en pacientes con úlcera de pie diabético tratados con Heberprot-P®. Rev cuba angiol y cir vasc. Ene-Jun 2014;15(1):13-21.

  8. Skrepnek GH, Mills JL, Armstrong DG (2015) A Diabetic Emergency One Million Feet Long: Disparities and Burdens of Illness among Diabetic Foot Ulcer Cases within Emergency Departments in the United States, 2006–2010. PLoS ONE 10: e0134914.

  9. González Acosta S, Calaña González Posada B, Marrero Rodríguez I, López Fernández R. Evolución clínica del tratamiento en el pie diabético con Heberprot-P o con el método convencional. Rev Cubana Angiol. y Cir Vasc. 2011;11(2):8—10.

  10. Gabriel S. ¿Por qué debemos preocuparnos del pie diabético?: Importancia del pie diabético. Rev Med Chile 2013; 141: 1464-1469 Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001100014&lng=es.

  11. Jara Albarrán A. Pie diabético. In: De la Cruz Fernández, M.J., Calle A, editors. Endocrinología. 2nd ed. Argentina: Panamericana; 2010. p. 703.

  12. Ruiz BC, Luis J, Legrand F, Hermida G, Hoyos YG. La terapia celular en el tratamiento de la isquemia critica de las extremidades inferiores. Electron J Biomed 2006;2(2):265-71.

  13. Rooke TW., Hirsch AT., Misra S. et al. ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline. J Am Coll Cardiol. 2011 Nov 1;58(19):2020-45

  14. Fernández Montequín JI. Una victoria de la Medicina Cubana en Angiología y Cirugía Vascular. Rev Cuba Angiol Cir Vasc. 2013 Ene-Jun; 14(1):45-53.

  15. Berlanga Acosta J. Heberprot-P: experimental background and pharmacological bases. Biotecnol Apl [Internet]. 2010 Jun [citado 2019 Jun 20]; 27(2): 88-94. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000200002&lng=es.




2020     |     www.medigraphic.com